ArticlePediatric cardiology2026
The Effect of Secondary Prophylaxis Adherence on Rheumatic Heart Disease and Determinants of Poor Adherence in Children: A 10-Year Retrospective Cohort Study.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rheumatic Heart Disease in Europe: Insights from a Pilot Screening Study and a Scoping Review.Global heart · 2026Article
- Epigenetic advances in rheumatic heart disease.Journal of translational autoimmunity · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic heart disease (RHD) remains the leading cause of acquired cardiovascular morbidity and mortality in children. Since secondary prophylaxis is the cornerstone of the management of acute rheumatic fever (ARF) and RHD, this study aimed to assess the impact of prophylaxis adherence on disease recurrence and cardiac outcomes and to identify causes of non-adherence with prophylaxis. We retrospectively reviewed 137 ARF cases diagnosed before the age of 18 years, with a minimum follow-up duration of ≥ 6 months. Diagnosis was based on the Revised Jones criteria. Clinical and echocardiographic evaluations were conducted to assess RHD, and prophylaxis adherence was evaluated through qualitative interviews. The cohort (49% female, mean age 13.97 ± 3.69 years) had a 43.8% rate of cardiac involvement at diagnosis, decreasing to 40.9% at last follow-up, with 38% developing RHD. RHD development was significantly associated with initial carditis presence and worse severity (p = 0.001; p = 0.046). Adherence to secondary prophylaxis was observed in 88.3% (n = 121). Low socioeconomic status, milder valvulitis at diagnosis, and longer follow-up duration were associated with non-adherence (p = 0.008; 0.041; 0.001). Adherent patients showed significant reductions in both the number of affected valves (p = 0.001) and severity of valvular regurgitation (p = 0.003). Recurrence was more frequent among non-adherent patients (p = 0.005). Non-adherence to secondary prophylaxis remains a major barrier in ARF/RHD control, as it correlates with more severe valvular involvement and recurrence. Identifying factors influencing adherence may guide future strategies to improve both prophylaxis adherence and long-term outcomes.
Indexed as
Identifiers
40879674What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.